title: A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.
abstract: BACKGROUND
  Recurrent glioblastoma is nearly always fatal, with median survival rates of approximately 12-14 months. Previous phase II clinical trials showed promising results with bevacizumab, alone or in combination with irinotecan, in patients with recurrent glioblastoma.
  
  
  OBJECTIVE
  To assess whether the survival of patients with recurrent glioblastoma receiving bevacizumab alone or with irinotecan in everyday practice is comparable to that reported in clinical trials.
  
  
  METHODS
  This was a retrospective observational study conducted at a single hospital in Italy.
  
  
  METHODS
  Patients with recurrent glioblastoma who had received bevacizumab alone or with irinotecan from January 2009 to September 2011 were included in our study.
  
  
  METHODS
  Progression-free survival (PFS) and overall survival (OS), and rates of PFS and OS at 6 months.
  
  
  RESULTS
  Median PFS was 5.1 months in the bevacizumab group (n = 9) and 15.4 months in the bevacizumab + irinotecan group (n = 10), with 6-month PFS rates of 45 and 69%, respectively. Median OS was 6.8 months for bevacizumab alone and 11.1 months for bevacizumab + irinotecan, with 6-month OS rates of 100 and 90%, respectively.
  
  
  CONCLUSIONS
  Although the number of patients included is not sufficient to allow a conclusive statement about the place of bevacizumab in the treatment of recurrent glioblastoma, the data appear promising, and are consistent with the results of clinical trials.
authors.affiliation: Pharmacy Department, Careggi Hospital, Florence, Italy. cecchim@aou-careggi.toscana.it
authors.forename: Michele
authors.initials: M
authors.lastname: Cecchi
authors.forename: Monica
authors.initials: M
authors.lastname: Vaiani
authors.forename: Marco
authors.initials: M
authors.lastname: Ceroti
authors.forename: Roberto
authors.initials: R
authors.lastname: Banfi
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D007558:Italy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D056687:Off-Label Use; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references.pmid: 19720927
references.citation: Drugs R D. 2003;4(5):285-91
references.pmid: 12952497
references.citation: J Clin Neurosci. 2012 Dec;19(12):1636-40
references.pmid: 23047061
references.citation: J Clin Oncol. 2009 Feb 10;27(5):740-5
references.pmid: 19114704
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Neurol Med Chir (Tokyo). 2010;50(9):713-9
references.pmid: 20885105
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Oncologist. 2009 Nov;14(11):1131-8
references.pmid: 19897538
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references.pmid: 17947719